Cytek Biosciences, Inc. CTKB
5.79 USD -0.10 (-1.70%)
At closeNov 10, 2026, 4:00 PM EST
5.79 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
5.65 Day range 5.89
3.31 52-week range 6.34
- YTD
- +14.65%
- 1 year
- +21.89%
News
benzinga.com Stephens & Co. Maintains Overweight on Cytek Biosciences, Raises Price Target to $7 Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $6 to $7.
globenewswire.com Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug…
seekingalpha.com Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
zacks.com Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.01 per share a year ago.
marketbeat.com Cytek Biosciences Q3 Earnings Call Highlights Cytek Biosciences NASDAQ: CTKB reported third-quarter 2026 revenue of $53.2 million, up 2% from a year earlier, as growth in the U.S. and demand for its high-end instruments helped offset weakness in…
benzinga.com Cytek Biosciences Q3 2026 Earnings Call Transcript Cytek Biosciences (NASDAQ:CTKB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Cytek Biosciences Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $53.229M Beat $52.800M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 25 percent decrease over losses of…
benzinga.com Cytek Biosciences Narrows FY2026 Sales Guidance from $207.000M-$212.000M to $208.000M-$211.000M vs $209.415M Est Cytek Biosciences (NASDAQ:CTKB) narrows FY2026 sales outlook from $207.000 million-$212.000 million to $208.000 million-$211.000 million vs $209.415 million estimate.
globenewswire.com Cytek Biosciences Reports Third Quarter 2026 Financial Results FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results…